/DNA
DNA Stock - Ginkgo Bioworks Holdings, Inc.
Healthcare|BiotechnologyNYSE
$8.10-1.64%
$0.14 (-1.64%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.13
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).72
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.58
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+11.1%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.02 – $8.18
TARGET (TP)$9.00
STOP LOSS$7.45
RISK/REWARD1:1.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.55
52W High$17.58
52W Low$5.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $227.04M | $251.46M | $477.71M | $313.84M | $76.66M |
| Gross Profit | $188.49M | $197.45M | $273.49M | $184.15M | $61.05M |
| Gross Margin | 83.0% | 78.5% | 57.3% | 58.7% | 79.6% |
| Operating Income | $-559,757,000 | $-864,406,000 | $-2,208,952,000 | $-1,828,467,000 | $-137,027,000 |
| Net Income | $-547,029,000 | $-892,869,000 | $-2,104,929,000 | $-1,830,047,000 | $-126,609,000 |
| Net Margin | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% |
| EPS | $-10.54 | $-18.37 | $-50.15 | $-53.83 | $-3.97 |
Company Overview
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
14%
Hold / Neutral
2
29%
Sell / Underperform
4
57%
Analyst Consensus🔴 Bearish
1 Bullish6 Neutral/Bearish
Price Targets
$4
Average Target
↓ 56.2% Downside
Now
$1
Low
$4
Average
$6
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 15th 2024 | BTIG Research | Downgrade | Sell | - |
| May 10th 2024 | William Blair | Downgrade | Underperform | - |
| November 14th 2023 | Raymond James | Downgrade | Market Perform | $2.5← $3.5 |
| November 9th 2023 | BTIG Research | Downgrade | Neutral | - |
| June 2nd 2023 | Goldman | Downgrade | Sell | $1.25← $3 |
| May 11th 2023 | William Blair | Downgrade | Market Perform | - |
| November 29th 2022 | Berenberg | Initiation | Buy | $6 |
| October 4th 2022 | Morgan Stanley | Initiation | Equal Weight | $5 |
| May 18th 2022 | BofA Securities | Downgrade | Underperform | $3 |
Earnings History & Surprises
DNABeat Rate
29%
Last 17 quarters
Avg Surprise
-40.9%
EPS vs Estimate
Beats / Misses
5/7
5 met exactly
Latest EPS
$-1.45
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-3.60vs$-3.60
Q2 24
0.0%
$-3.20vs$-3.20
Q3 24
0.0%
$-3.20vs$-3.20
Q4 24
+55.0%
$-1.08vs$-2.40
Q1 25
-25.5%
$-1.82vs$-1.45
Q2 25
-28.5%
$-1.58vs$-1.23
Q3 25
+23.6%
$-1.10vs$-1.44
Q4 25
-16.9%
$-1.45vs$-1.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $-1.80 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.24 | $-1.45 | -16.9% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.44 | $-1.10 | +23.6% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.23 | $-1.58 | -28.5% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $-1.45 | $-1.82 | -25.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-2.40 | $-1.08 | +55.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-3.20 | $-3.20 | 0.0% | = MET |
Q2 2024 | May 9, 2024 | $-3.20 | $-3.20 | 0.0% | = MET |
Q1 2024 | Feb 29, 2024 | $-3.60 | $-3.60 | 0.0% | = MET |
Q4 2023 | Nov 8, 2023 | $-3.60 | $-3.60 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $-3.60 | $-3.60 | 0.0% | = MET |
Q2 2023 | May 10, 2023 | $-3.60 | $-3.20 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 1, 2023 | $-12.00 | $-1.60 | +86.7% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-10.00 | $-16.00 | -60.0% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-2.00 | $-16.40 | -720.0% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-1.60 | $-2.00 | -25.0% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-2.00 | $-0.40 | +80.0% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-1.60 | $-2.80 | -75.0% | ✗ MISS |
Q3 2021 | Sep 20, 2021 | — | $-1.67 | — | — |
Q2 2021 | May 24, 2021 | — | $-2.28 | — | — |
Latest News
Ginkgo Bioworks Completes Initial Collaboration With Agricen
➖ NeutralBenzinga•Dec 17, 2025, 01:09 PM
ProteoNic's 2G UNic Technology Licensed By Ginkgo Bioworks For Use In $22.2M Project Awarded To Ginkgo By Biomedical Advanced Research And Development Authority
📈 PositiveBenzinga•Dec 11, 2025, 01:49 PM
Ginkgo Bioworks Partners Woth Deep Origin On 4.5-Year Project Funded By Advanced Research Projects Agency For Health Computational ADME-Tox And Physiology Analysis For Safer Therapeutics Program.
📈 PositiveBenzinga•Dec 9, 2025, 01:07 PM
Ginkgo Bioworks Awarded 4-Yr, Up To $47M Contract By EMSL To Co-Design, Build, And Integrate High‑Throughput Automated Phenotyping Platform In Support Of M2PC
📈 PositiveBenzinga•Dec 5, 2025, 01:42 PM
Ginkgo Bioworks Holdings shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 7, 2025, 07:25 PM
Ginkgo Bioworks Holdings Affirms FY2025 Sales Guidance of $167.000M-$187.000M vs $177.075M Est
➖ NeutralBenzinga•Nov 6, 2025, 09:15 PM
Ginkgo Bioworks Holdings Q3 EPS $(1.45) Misses $(1.24) Estimate, Sales $38.837M Miss $38.850M Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:14 PM
Ginkgo Bioworks Awarded Up To $22.2M Contract From Biopharmaceutical Manufacturing Preparedness Consortium To Develop Innovations To Lower Costs Of Local Biomanufacturing Of Monoclonal Antibodies
📈 PositiveBenzinga•Nov 3, 2025, 01:13 PM
Ginkgo Bioworks Extends Its Multi-Year Partnership With Bayer To Continue Developing Biological Products For Agriculture, Focusing On Microbial Nitrogen Fixation
📈 PositiveBenzinga•Oct 31, 2025, 12:03 PM•Also:
Ginkgo Bioworks Collaborates With STRM.BIO And University Of British Columbia To Develop In Vivo Chimeric Antigen Receptor Therapies For Autoimmune Diseases
📈 PositiveBenzinga•Oct 23, 2025, 12:20 PM
BTIG Maintains Sell on Ginkgo Bioworks Holdings, Raises Price Target to $9
➖ NeutralBenzinga•Aug 25, 2025, 12:23 PM
Ginkgo Bioworks Announces Strategic Partnership To Scale AI Drug Discovery Via Datapoints Platform
📈 PositiveBenzinga•Aug 20, 2025, 12:06 PM
Frequently Asked Questions about DNA
What is DNA's current stock price?
Ginkgo Bioworks Holdings, Inc. (DNA) is currently trading at $8.10 per share. The stock has moved -1.64% today.
What is the analyst price target for DNA?
The average analyst price target for DNA is $9.00, based on 1 analyst.
What sector is Ginkgo Bioworks Holdings, Inc. in?
Ginkgo Bioworks Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is DNA's market cap?
Ginkgo Bioworks Holdings, Inc. has a market capitalization of $0.44 billion, making it a small-cap company.
Does DNA pay dividends?
No, Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
ATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to DNA for comparison